NEW YORK, NY – As October marks Breast Cancer Awareness Month, the familiar landscape of pink ribbons often dominates public discourse, focusing heavily on early detection and the successful completion of primary treatment. Yet, for thousands of individuals, the reality of breast cancer is far more complex and enduring. On October 13, National Metastatic Breast Cancer Awareness Day, a global movement is set to shift the narrative. More than 325 landmarks across 20 countries, 195 cities, and all 50 U.S. states will illuminate in teal, green, and pink—the official colors of metastatic breast cancer (MBC)—to demand attention, funding, and, ultimately, a cure for the disease that remains the leading cause of breast cancer-related deaths.
The Reality of Stage 4: Defining the Invisible Struggle
Metastatic breast cancer, or Stage 4, occurs when cancer cells migrate from the original site in the breast to distant organs, most commonly the bones, liver, lungs, or brain. Contrary to common misconceptions, even when found in other organs, it remains breast cancer. The diagnosis represents a permanent shift in a patient’s life; while some are diagnosed at Stage 4 from the outset, others face the harrowing reality of a recurrence months, years, or even decades after their initial treatment.
For those living with MBC, there is no “finishing” treatment. The disease is currently incurable. Therapy, while essential, is a lifelong, ongoing endeavor aimed at controlling the spread, extending life, and maintaining quality of life. Patients often face a grueling cycle of treatments, as the cancer frequently develops resistance to therapies, forcing them to pivot to new, often more aggressive, interventions.
The human cost is staggering. In the United States alone, an estimated 42,670 people are expected to lose their lives to breast cancer in 2026. This translates to approximately 117 deaths every single day. These statistics are not merely numbers; they represent mothers, fathers, siblings, and friends, underscoring the urgent necessity for research that goes beyond the early-stage focus of conventional awareness campaigns.
A Chronology of Advocacy: From a Single Light to a Global Beacon
The #LightUpMBC campaign has evolved from a deeply personal mission into a worldwide phenomenon. The initiative was founded by Laura Inahara, driven by the loss of her best friend, Jessica Moore, who succumbed to metastatic breast cancer at the age of 36.
- 2017: The journey began with a single, localized effort. The Memorial Bridge in Portsmouth, New Hampshire, became the first landmark to illuminate in honor of those fighting MBC. It was a modest beginning, but it planted the seed for a much larger movement.
- 2020–2025: As the awareness grew, so did the participation. The campaign expanded from a regional gesture to a national, and eventually international, event. By leveraging social media and community advocacy, #LightUpMBC began to coordinate simultaneous lightings, creating a visual wave of solidarity that swept across time zones.
- 2026: This year marks a historic milestone for the campaign. With over 325 participating landmarks—including global icons such as One World Trade Center, the Willis Tower in Chicago, Philadelphia City Hall, Niagara Falls, and the Ness Bridge in Scotland—the initiative has solidified its position as the premier fundraising engine for metastatic research.
The evolution of the campaign serves as a testament to the power of patient-led advocacy. What began as an attempt to shine a light on a neglected corner of cancer research has grown into a $2.7 million funding force, fundamentally changing how METAvivor approaches the scientific community.
Supporting Data: Why Targeted Research Matters
The distinction between early-stage breast cancer and metastatic disease is not merely semantic; it is a fundamental difference in clinical approach. Because MBC is a systemic disease, local treatments like surgery or radiation are often insufficient. Patients require systemic therapies that can reach cancer cells wherever they have traveled in the body.
According to METAvivor, the primary obstacle to improving survival rates is the lack of funding dedicated specifically to metastatic research. While general breast cancer research is well-funded, a disproportionately small percentage of those funds is earmarked for the specific needs of Stage 4 patients.
METAvivor fills this critical gap. As a 501(c)(3) nonprofit, the organization exclusively funds Stage 4 research. Their selection process is rigorous, utilizing a dual-track review system that involves both scientific peers and patient advocates. This ensures that the projects funded are not only scientifically sound but also relevant to the actual lived experience and clinical needs of the metastatic community.
The focus of this research is twofold:
- Developing Targeted Therapies: Research into the genetic and molecular drivers of metastasis to stop the spread.
- Quality of Life Preservation: Investigating drug combinations that minimize toxicity while maximizing the efficacy of disease control.
Official Responses: Voices from the Frontlines
The leadership behind the #LightUpMBC campaign and METAvivor emphasizes that the initiative is about more than just buildings glowing in the night; it is about humanizing the data.
Dr. Kelly Shanahan, Board President of METAvivor, offers a perspective that is both clinical and profoundly personal. Diagnosed in 2013, Dr. Shanahan has lived with the reality of Stage 4 for 13 years—a duration she admits she never expected to reach. "My hope and the hope of so many others lies in research," she stated. "METAvivor-funded research is increasingly important these days. #LightUpMBC is the biggest contributor to this research and is also a way to bring us together as a community."
Laura Inahara, the founder of #LightUpMBC, views the campaign as the ultimate tribute to her late friend. "Jessica hoped to illuminate one local landmark," Inahara remarked. "Today, her legacy helps families around the world shine a light for the people they love, teaches patients with MBC how to advocate for themselves, and has now raised over $2.7 million for critical MBC research."
The campaign’s reach is also supported by the arts community, with Broadway stars and performers lending their platforms to the cause. This interdisciplinary approach—combining science, patient advocacy, and the arts—is designed to dismantle the stigma and isolation that often accompany a Stage 4 diagnosis.
Implications: The Path Toward a Survivable Future
The goal of the #LightUpMBC movement is clear: to transform metastatic breast cancer from a terminal diagnosis into a manageable, chronic, and eventually curable condition.
The implications of this year’s campaign are far-reaching. By bringing together scientific experts, patients, and the public, #LightUpMBC creates an ecosystem of support. The upcoming live stream, #LightUpMBC Live, will be hosted by Tami Eagle Bowling—who has been living with MBC for 11 years—and Broadway performer Kara Lindsay. The event will serve as a hub for education, featuring insights from researchers and stories from those living with the disease.
The program is set to include performances from high-profile artists, including Victoria Clark, Dorian Harewood, and Christina Bianco. These performances serve as a reminder that behind the medical charts and the clinical statistics, there are individuals whose lives are vibrant, meaningful, and worth fighting for.
How to Engage
The public is encouraged to participate in this global movement on October 13.
- The Live Stream: Tune in at 8 p.m. ET / 5 p.m. PT on the METAvivor YouTube channel, Facebook Live, or via LiveOne.
- Social Advocacy: Participants are encouraged to photograph participating landmarks and share them on social media using the hashtags #LightUpMBC and #METAvivor, tagging @LightUpMBC to maximize digital reach.
- Direct Support: 100% of the net proceeds from the campaign go directly to research. Donations and a full list of participating landmarks can be found at www.lightupmbc.org.
As the world turns its eyes to the illuminated landmarks this October 13, the message will be unmistakable: the shadows of metastatic breast cancer are being challenged by the collective light of a community that refuses to give up. The fight for survival is ongoing, but for the first time in history, the path to a future where MBC is a survivable condition is being illuminated with global unity.
About the Author
